Caris Life Sciences Financial Ratios
NASDAQ: CAIHealth CareMedical SpecialitiesUSD
29.70+2.20 (+8.00%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Caris Life Sciences ratio analysis
Caris Life Sciences earned a net margin of -8.4% in FY 2025, up from -68.4% a year earlier. Return on equity reached -11.8%, meaning Caris Life Sciences generated -0.12 dollars of profit for every dollar of shareholders' equity. Debt-to-equity stood at 0.66, and the current ratio was 7.85.
Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Caris Life Sciences financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Price / sales | 5.56 | — | — |
| Price / book | 7.81 | — | — |
| Operating margin | 5.6% | -62.4% | -104.4% |
| Net margin | -8.4% | -68.4% | -111.5% |
| Free cash flow margin | 8.2% | -61.5% | -97.5% |
| Return on equity (ROE) | -11.8% | — | — |
| Return on assets (ROA) | -6.0% | -82.0% | — |
| Debt / equity | 0.66 | — | — |
| Current ratio | 7.85 | 1.30 | — |
| Revenue growth | 97.0% | 34.7% | — |